Clinical Trials · NCT01382719
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Palatin Technologies, Inc
- Enrollment
- 612
- Start date
- Jun 2011
- Locations
- 68 sites, United States, Canada
- Primary endpoint
- The Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE)